NewGenIvf
NIVF
1 hedge funds and large institutions have $10.8K invested in NewGenIvf in 2025 Q2 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 3 closing their positions.
0% less ownership
Funds ownership: 0% → 0% (-0%)
67% less funds holding
Funds holding: 3 → 1 (-2)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
74% less capital invested
Capital invested by funds: $41.7K → $10.8K (-$30.9K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MG
Marex Group
London,
|
+$28.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$17K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$15.9K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$7.21K |
| 4 |
MI
MMCAP International
Grand Cayman,
Cayman Islands
|
-$1.6K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$64 |
NIVF Hedge Fund Activity: Q2 2025 in Review
1 of the 7,612 institutional investors tracked by Wall St. Rank reported a position in NewGenIvf (NIVF) for Q2 2025, worth a combined $10.8K — down 74% from $41.7K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of NIVF and 1 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.
The largest buyer was Marex Group, opening a new position worth an estimated $28.5K. The largest seller was Virtu Financial, exiting entirely with an estimated $17K sold.
- 1 institutional investor held NewGenIvf (NIVF) as of Q2 2025, down from 3 in Q1 2025.
- Funds reported $10.8K of NewGenIvf stock for Q2 2025, down 74% quarter-over-quarter.
- 1 fund opened new NewGenIvf positions in Q2 2025 and 3 closed out, a net change of -2 holders.
- The largest NewGenIvf buyer in Q2 2025 was Marex Group, an estimated $28.5K added.
- The largest NewGenIvf seller in Q2 2025 was Virtu Financial, an estimated $17K sold.
Based on aggregated 13F filings for Q2 2025.